Nicox to present at the 14th Annual BIO Investor Forum
...................................
October 13, 2015
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the 14th Annual BIO Investor Forum in San Francisco on Tuesday October 20, 2015, at 10:00 am Pacific Time.
A live webcast of the BIO Investor Forum presentation can be accessed under the "Presentations & webcasts" page within the News & Media section of the company's website at www.nicox.com. A replay of the webcast will be archived on the Nicox website for 90 days following the date of the presentation.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.
Nicox's advanced pipeline features VESNEO(TM) for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was recently submitted to the FDA by the Company's licensee Valeant. Our pipeline also features: AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis; AzaSite®, a pre-MAA candidate in Europe for bacterial conjunctivitis; and BromSite(TM), a pre-MAA candidate in Europe for pain and inflammation after cataract surgery. The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe's five largest markets complemented by an expanding international network of distributors.
Nicox is headquartered in France and has more than 130 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com.
Upcoming 2015 events
Financial and business conferences
Nov.5 Société Générale Healthcare Forum Paris, France
Nov. 12-13 Bryan Garnier Healthcare Conference Paris, France
Nov.20-21 Actionaria 2015 Paris, France
Nov.24 Natixis MidCap Conference Paris, France
Scientific conferences
Nov. 14-17 AAO - American Academy of Ophthalmology Las Vegas, US
Nov. 27-30 SOI National Congress Rome, Italy
| Analyst coverage Bryan, Garnier & Co Hugo Solvet Paris, France Stifel Max Herrmann London, UK Invest Securities Martial Descoutures Paris, France Kepler Cheuvreux Alexandra Ralli Paris, France |   |
...................................
Contacts
Nicox Gavin Spencer | Executive Vice President Corporate Development
Caroline Courme | Communication Manager
Tel +33 (0)4 97 24 53 43 | communications@nicox.com
Media Relations
United Kingdom Jonathan Birt
Tel +44 7860 361 746 | jonathan.birt@ymail.com
France NewCap | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 | nicox@newcap.fr
United States Argot Partners | Eliza Schleifstein
Tel +1 (917) 763-8106 | eliza@argotpartners.com
Investor Relations
Europe NewCap | Julien Perez | Valentine Brouchot
Tel +33 (0)1 44 71 94 94 | nicox@newcap.fr
United States Argot Partners | Melissa Forst
Tel +1 (212) 600-1902 | melissa@argotpartners.com
...................................
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2014' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website (www.nicox.com).
